
Aquaclav 625mg Tablet by 14
Please be aware that prices may vary due to fluctuations in the market, and adjustments may be made without advance notice.
Aquaclav 625mg tablets contain a combination of amoxicillin and clavulanate potassium, it used to treat a broad range of bacterial infections like sinusitis
₦8,000.00
Buy NowIndication | Dosage Instructions and Maximum Daily Dose |
---|---|
Bacterial Infections (Respiratory Tract, Urinary Tract, Typhoid, Skin & Soft Tissue, Dental Infections, and Bone & Joint Infections) | Adults & Children (12 years and above): 1 tablet twice daily (every 12 hours). Maximum daily dose: 2 tablets (1250mg) per day. |
Bacterial Infections in Children (Otitis Media, Tonsillitis, and Skin Infections) | Children (below 12 years): Dosage is based on body weight and should be determined by a healthcare provider. Aquaclav 625mg tablets are generally not recommended for children under 12 due to high dosage. |
Bacterial Infections in the Elderly | Elderly: Same as adults, unless otherwise directed by a healthcare provider. Dose adjustment may be required for those with kidney or liver impairment. |
Important Information
- Storage: Store in a cool, dry place below 25°C, away from moisture and sunlight. Keep out of reach of children.
- Pregnancy & Breastfeeding: Can be used during pregnancy and breastfeeding, but only under the supervision of a healthcare provider.
- Possible Side Effects: Common side effects include diarrhea, nausea, vomiting, and skin rash. If you experience severe allergic reactions, persistent diarrhea, or yellowing of the eyes or skin, consult a healthcare provider immediately.
- Drug Interactions: May interact with blood thinners (like warfarin) and other antibiotics. Inform your healthcare provider about all other medications and supplements you are taking.
- Usage Note: Take with or immediately after food to reduce the risk of stomach upset. Complete the full course of treatment, even if you feel better before the medication is finished.
Reviews
There are no reviews yet.